MYB is a transcription factor that recognizes the DNA sequence 5'-YAAC[GT]G-3' and serves as a critical regulator of hematopoietic cell proliferation and differentiation 1. The protein functions through dual mechanisms: it transactivates genes promoting cell cycle progression, such as cyclin A1 in myeloid cells 2, while also regulating genes involved in apoptosis prevention 3. MYB is frequently dysregulated in human malignancies through multiple mechanisms, including chr6 translocations that result in fusion proteins (e.g., t(6;9) generating MYB-NFIB fusions in breast and head/neck carcinomas) 4 and gene truncations that remove microRNA-binding sites, leading to overexpression 5. MYB is overexpressed in acute myeloid leukemia, T-cell acute lymphoblastic leukemia, and solid tumors, establishing it as a bona fide oncogene 1. Clinically, dysregulated MYB creates "tumor-specific dependency" in blood cancers, making it an attractive therapeutic target 6. Therapeutic strategies focus on disrupting MYB's interaction with cofactors like EP300/CBP through small-molecule inhibitors and peptide mimetics 6. In gliomas, MYB/MYBL1 alterations define a newly recognized WHO classification category of pediatric-type diffuse low-grade gliomas 5.